Anatomic Molecular Pathology: An Emerging Field

Similar documents
Molecular Diagnosis for Colorectal Cancer Patients

Serrated Polyps and a Classification of Colorectal Cancer

Colorectal cancer Chapelle, J Clin Oncol, 2010

Lynch Syndrome Screening for Endometrial Cancer: Basic Concepts 1/16/2017

Immunotherapy in Colorectal cancer

Measure Description. Denominator Statement

Colon Cancer and Hereditary Cancer Syndromes

Evolution of Pathology

Development of Carcinoma Pathways

Resource impact report: Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27)

CAP Laboratory Improvement Programs. Summary of Microsatellite Instability Test Results From Laboratories Participating in Proficiency Surveys

Molecular biology of colorectal cancer

TumorNext-Lynch. genetic testing for hereditary colorectal or uterine cancer

Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer

Introduction. Why Do MSI/MMR Analysis?

Colon cancer: practical molecular diagnostics. Wade S. Samowitz, M.D. University of Utah and ARUP

Microsatellite instability and other molecular markers: how useful are they?

Molecular markers in colorectal cancer. Wolfram Jochum

Clinicopathologic Characteristics of Left-Sided Colon Cancers with High Microsatellite Instability

Marcatori biomolecolari dei carcinomi del colon-retto sporadici ed ereditari

Current Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors)

Assessment of Universal Mismatch repair (MMR) or Microsatellite Instability (MSI) testing in colorectal cancers.

Molecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine

A Review from the Genetic Counselor s Perspective

Policy Specific Section: Medical Necessity and Investigational / Experimental. October 14, 1998 March 28, 2014

Current and future applications of Molecular Pathology. Kathy Walsh Clinical Scientist NHS Lothian

Universal Screening for Lynch Syndrome

ASSESSMENT OF MLH1 PROMOTER METHYLATION IN ENDOMETRIAL CANCER USING PYROSEQUENCING TECHNOLOGY OBJECTIVES

LYNCH SYNDROME: IN YOUR FACE BUT LOST IN SPACE (MOUNTAIN)!

Agenda 8:30 AM. Jennifer L. Hunt

High risk stage II colon cancer

COLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer

What Pathology can tell us in the approach of localized colorectal cancer

Colorectal Carcinoma Reporting in 2009

COLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer

The Whys OAP Annual Meeting CCO Symposium September 20. Immunohistochemical Assessment Dr. Terence Colgan Mount Sinai Hospital, Toronto

Dr. Pravin D. Potdar. M.Sc, Ph.D, D.M.L.T.,DHE, DMS

Yes when meets criteria below. Dean Health Plan covers when Medicare also covers the benefit.

Case Study. Overview. Deleterious MLH1 mutation detected on sequencing 10/16/2014

Genetic Testing for Lynch Syndrome

Biomarkers to optimize treatment selection in colorectal cancer Edwin Pun HUI, MBChB, MD, FRCP (Lond & Edin)

Updates in Gynecologic Oncology. Todd Boren, MD Gynecologic Oncologist Chattanooga s Program in Women s Oncology Sept 8 th, 2018

SALSA MS-MLPA KIT ME011-A1 Mismatch Repair genes (MMR) Lot 0609, 0408, 0807, 0407

Prior Authorization. Additional Information:

National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant

BRAF Testing In The Elderly: Same As in Younger Patients?

Transform genomic data into real-life results

and management of lung cancer Maureen F. Zakowski, M.D. Memorial Sloan-Kettering Cancer Center

Personalized Genetics

Precision Genetic Testing in Cancer Treatment and Prognosis

Case Presentation Diana Lim, MBBS, FRCPA, FRCPath Senior Consultant Department of Pathology, National University Health System, Singapore Assistant Pr

GENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By. Magnitude of the Problem. Magnitude of the Problem. Cardinal Features of Lynch Syndrome

National Medical Policy

1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011?

VENTANA MMR IHC Panel Interpretation Guide for Staining of Colorectal Tissue

Applying Genomics to Cancer 21 st September The Frequency of EGFR mutations in Lung Adenocarcinoma: The Cardiff Experience

NGS ONCOPANELS: FDA S PERSPECTIVE

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors

Corporate Medical Policy

Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes

Beyond the APC era Alternative pathways to CRC. Jeremy R Jass McGill University

Matthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory

Familial and Hereditary Colon Cancer

Colonic polyps and colon cancer. Andrew Macpherson Director of Gastroentology University of Bern

Histo-prognostic factors what histopathology has to offer for clinical decision making

7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview

Risk of Colorectal Cancer (CRC) Hereditary Syndromes in GI Cancer GENETIC MALPRACTICE

La genetica del carcinoma colo-rettale

B Base excision repair, in MUTYH-associated polyposis and colorectal cancer, BRAF testing, for hereditary colorectal cancer, 696

Colorectal Cancer - Working in Partnership. David Baty Genetics, Ninewells Hospital

Content. Diagnostic approach and clinical management of Lynch Syndrome: guidelines. Terminology. Identification of Lynch Syndrome

Immunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC

Molecular Testing in Lung Cancer

Familial and Hereditary Colon Cancer

Management of higher risk of colorectal cancer. Huw Thomas

Molecular Biomarkers in the Characterization & Treatment of Colorectal Carcinoma

Genetic Testing for Inherited Susceptibility to Colon Cancer; Including Microsatellite Instability Testing. Original Policy Date

Célia DeLozier-Blanchet

Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory

Change Log V1.3- v1.4

General Session 7: Controversies in Screening and Surveillance in Colorectal Cancer

NGS IN ONCOLOGY: FDA S PERSPECTIVE

The Next Generation of Hereditary Cancer Testing

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal

Genetic Modifiers of Chemotherapy for Colorectal Cancer

LUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia

A Molecular Update for Cytopathology

Personalized Medicine: Lung Biopsy and Tumor

DIAGNOSTICS ASSESSMENT PROGRAMME Diagnostics consultation document

Microsatellite instability and other molecular markers: how usefulare they? Pr Frédéric Bibeau, MD, PhD Pathology Department CHU de Caen France

The Role of the CpG Island Methylator Phenotype on Survival Outcome in Colon Cancer

MRC-Holland MLPA. Description version 28; 4 January 2018

Molecular Testing for Gastrointestinal Cancer

MET skipping mutation, EGFR

Early (and not so early) colorectal cancer: The pathologist s point of view

Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011

Molecular mechanisms of human carcinogenesis

Harmesh Naik, MD. Hope Cancer Clinic PERSONALIZED CANCER TREATMENT USING LATEST IN MOLECULAR BIOLOGY

Lynch Syndrome. Angie Strang, PGY2

The College of American Pathologists (CAP) offers these

Transcription:

Anatomic Molecular Pathology: An Emerging Field Antonia R. Sepulveda M.D., Ph.D. University of Pennsylvania asepu@mail.med.upenn.edu 2008 ASIP Annual Meeting

Anatomic pathology (U.S.) is a medical specialty that is concerned with the diagnosis of disease based on the gross, microscopic, and molecular examination of organs, tissues, and cells. Molecular pathology Molecular pathology is an emerging discipline within anatomical pathology which is focused on the use of nucleic acid based techniques such as in situ hybridization, reverse transcription, PCR, and nucleic acid microarrays for specialized studies of disease in tissues and cells. Molecular pathology shares some aspects of practice with both anatomic and clinical pathology, and is sometimes considered a "crossover" discipline.

Anatomic Pathology Surgical Pathology Surgical resection specimens Diagnosis, staging Prognostic/predictive markers Biopsies diagnostic, staging Prognostic/predictive markers Cytopathology Cells in biological fluids Fine needle aspiration Autopsy Pathology

Surgical Pathology Surgical specimen Sampling Paraffin embedded tissue

Surgical Pathology SR08 6XX Diagnosis: Moderately differentiated adenocarcinoma

Molecular Tests in Anatomic Tumor tissue Pathology Mutational analysis: EGFR, BRAF, Kras,, LOH Microsatellite Instability & DNA MMR IHC CpG methylation: hmlh1 Chromosomal Translocations Gene expression profiles predictive predictive markers Microarray gene expression profiles MicroRNA profiles Proteomic testing Non neoplastic neoplastic Infectious agents Other Identity tests (STR panels) Other

Tissue Based Molecular Tests for Hereditary Nonpolyposis colorectal Cancer (HNPCC) Workup

HNPCC and DNA Mismatch Repair Proteins MutS: MSH2, MSH6,, MSH3 MutL: MLH1, PMS2,, MLH3 MMR proteins function as heterodimers The heterodimers are required for protein stability Hereditary Nonpolyposis Colorectal Cancer (HNPCC): 1 Loss of function/expression of DNA mismatch repair protein in tumors (germline mutation) 2 Mutator Phenotype: Microsatellite Instability (MSI)

Algorithm for Laboratory Testing for HNPCC MSI Lindor, NM et al. JAMA, 296 (12), 2006 MLH1 methyl and/or BRAF mut

TESTING MSI IN TUMORS PROTOCOL Unstained sections from formalin fixed paraffin embedded tissue Scrape selected areas for DNA extraction PCR amplification with MSI panel DNA fragment characterization by electrophoresis

COLORECTAL ADENOCARCINOMA: High Level Microsatellite Instability (MSI H) Loss of hmlh1 Protein Expression N N N N Gologan & Sepulveda et al. Arch Pathol Lab Med 2005; 129: 1390 1397 T T T T BAT25 BAT26 D5S346 D17S250

Incidence and functional consequences of hmlh1 promoter hypermethylation in colorectal carcinoma 11 of 13 (84%) MSI positive cancers exhibited prominent methylation, compared with 2 of 21 MSI negative cancers (P =0.0001). Methylation specific PCR (MSP) James G. Herman et al. and Stephen B. Baylin PNAS, Vol. 95, Issue 12, 6870 6875, 6875, 1998

Distinction of HNPCC and Sporadic Microsatellite Unstable CRC through Quantification of MLH1 Methylation by Real time PCR M Bettstetter et al and W Dietmaier. Clinical Cancer Research 13, 3221 3228, 3228, 2007

BRAF Mutation is Frequently Present in Sporadic CRC with Methylated hmlh1, but not in HNPCC BRAF: cytoplasmic serine/threonine kinase Function: mitogen activated protein kinase signaling pathway Most of the mutations in BRAF : thymine to adenine transversion at nucleotide 1796 Substitution of valine for glutamate (V600E) Results in BRAF activating mutation BRAF V600E mutations occur in: Sporadic MSI H H CRC (40 74%) Sporadic MSS CRC 4% to 12% BRAF V600E mutations not detected in HNPCC patients G Deng et al. and YS Kim Clin Cancer Res, 10, 191 195, 2004

EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TESTING IN LUNG CANCER

Molecular Diagnosis in Lung Cancer NCCN Practice Guidelines (v.2.2008) EGFR mutations define a subgroup of NSCLC patients who will benefit from EGFR tyrosine kinase inhibitor (TKI) treatment

Distribution of Mutations and Response Rate to TKI EX19 DEL ~90% Not all EGRF mutations associated with response L858R Cancer Science (OnlineEarly Articles). doi:10.1111/j.1349 7006.2007.00607.x

Detection of EGFR Exon 19 Deletions Exon 19 In frame deletions usually 9 24 bp Positive for deletion 208 bp 190 bp = 18 bp Normal

Oncotype DX is validated for use in breast cancer patients Multigene Expression Assay (RT PCR) to Predict Recurrence of Tamoxifen Treated, Node Negative Negative Breast Cancer Selection of Patients for Chemotherapy S.Paik et al. NEJM. 351:2817 2826, 2826, 2004

Pathwork Tissue of Origin Test Gene expression microarray based test Helps identify tissue of origin of poorly & undifferentiated cancers 15 tissue types CancerTYPE Molecular Classification Test 92 gene real time quantitative PCR assay Molecular classification of human cancers 39 tumor classes

Molecular Diagnosis of Infectious Agents Whipple s disease: Tropheryma whipellii Test: PCR for rrna DNA sequence Confirmation of diagnosis and follow up

The Molecular Anatomic Pathology Laboratory Anatomic Pathology Molecular Diagnostics yeinjee.com/.../2007/08/paris louvre pyramid.jpg

Career Opportunities in Molecular Anatomic Pathology Environment: Academia, Hospitals, Reference Laboratories and Industry Positions Scientific Directors Research and Clinical Technicians and Technologists Roles: Translational research Test development Validation and clinical testing

Acknowledgments: Vivianna Van Deerlin MD, Univ. Pennsylvania